Clinical Trial Detail

NCT ID NCT02612194
Title LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Earle Burgess
Indications

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

ureter transitional cell carcinoma

urethra transitional cell carcinoma

Therapies

Crizotinib

Age Groups: adult

No variant requirements are available.